Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMBZN7J)

Drug Name	Litifilimab DMBZN7J
Synonyms	BIIB059
Drug Type	Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Systemic lupus erythematosus	DISI1SZ7	4A40.0	Phase 3	[1]
Cutaneous lupus erythematosus	DISOIX6L	EB5Z	Phase 3	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05352919) A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05531565) A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST). U.S.National Institutes of Health.